Phenolic melanin precursors provide a rational approach to the design of antitumor agents for melanoma.
A unique biological property of the melanocyte, melanin synthesis may permit a rational approach to design agents for better management of malignant melanoma. This in vivo and in vitro study examined the selective melanocytotoxicity and antimelanoma effects of phenolic compounds, cysteinylphenol (CP), cysteaminylphenol (CAP), and related compounds, and found (1) that both 4-S-CP and 4-S-CAP are melanin precursors, (2) that 4-S-CAP possesses a marked depigmenting potency with selective destruction of melanocytes in black follicles, and (3) a significant inhibition in the protein synthesis and tumor growth of B16 melanoma. Importantly, a whole body autoradiography indicated that these phenolic melanin precursors are selectively incorporated into melanoma tissues after i.p. administration.
Jimbow
K
K
Division of Dermatology and Cutaneous Sciences, University of Alberta, Edmonton, Canada.
Miura
T
T
Ito
S
S
Ishikawa
K
K
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D003543:Cysteamine / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D003545:Cysteine / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D008543:Melanins / Q000378:metabolism*; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains
D000970:Antineoplastic Agents; D008543:Melanins; D003543:Cysteamine; C043036:4-S-cysteinylphenol; C043037:4-S-cysteaminylphenol; D003545:Cysteine